Expeditors International of Wshngtn Inc vs 10X Genomics Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $182.04 (market cap $23.24B), while 10X Genomics Inc trades at $45.49 (market cap $5.81B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 4× 10X Genomics Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.91% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| EXPD | TXG | |
|---|---|---|
Market Cap | $23.24B | $5.81B |
Sector | Industrials | Health |
52-Week High | $178.22 | $45.80 |
52-Week Low | $111.37 | $11.34 |
Enterprise Value | $22.49B | $5.35B |
Dividend Yield | 0.91% | — |
Signals from Pluang's Aura AI — not financial advice
Expeditors International (EXPD) trades at $178.22, up 1.55% on the day, and has consistently beaten earnings estimates in recent quarters. The stock shows strong technical momentum with a bullish moving average signal, though oscillators suggest overbought conditions. Fundamentally, the company maintains robust profitability with a 7.48% net margin and 36.59% ROE, supported by positive operating cash flow of $1.01B in 2025. Recent news highlights the stock's inclusion on strong buy lists and its resilience in the transportation services sector.
The outlook is mixed with strong fundamentals and positive earnings momentum offset by a cautious analyst consensus and elevated valuation multiples. The primary opportunity lies in continued execution and e-commerce demand driving intermodal services, while risks include industry freight downturns, economic uncertainties, and the stock trading above the consensus price target of $161.50.
TXG is trading at $45.80, up 9.65% today, showing strong momentum despite mixed analyst sentiment. The stock exhibits bullish technical signals with positive moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company continues to report revenue growth with improving margins, narrowing losses from -$166M in 2022 to -$44M in 2025. Recent developments include strategic acquisitions and research collaborations that strengthen its life sciences technology position.
The outlook remains cautiously optimistic as TXG demonstrates operational improvement and strategic positioning in genomics technology. Key opportunities include continued margin expansion and platform adoption, while risks involve persistent profitability challenges and competitive pressures. Analyst consensus shows divided opinions with a $37.71 price target below current levels, suggesting potential near-term volatility despite long-term growth prospects.
Trailing returns across standard periods
Latest headlines on both assets
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →